Advances in vasospasm treatment and prevention

Ricardo J. Komotar, Brad E. Zacharia, Ricky Valhora, J. Mocco, E. Sander Connolly

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Outcome after aSAH depends on several factors, including the severity of the initial event, perioperative medical management, surgical variables, and the incidence of complications. Cerebral vasospasm (CV) is ure to consistently respond to treatment, emphasizing the need for further research into the underlying mechanisms of SAH-induced cerebrovascular dysfunction. To this end, our paper reviews the relevant literature on the main therapies employed for CV after aSAH and discusses possible avenues for future investigations. Current management of this condition consists of maximal medical therapy, including triple H regimen and oral administration of calcium antagonists, followed by endovascular balloon angioplasty and/or injection of vasodilatory agents for refractory cases. As the precise pathophysiology of CV is further elucidated, the development of promising investigational therapies will follow.

Original languageEnglish (US)
Pages (from-to)134-142
Number of pages9
JournalJournal of the neurological sciences
Issue number1-2
StatePublished - Oct 15 2007

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Advances in vasospasm treatment and prevention'. Together they form a unique fingerprint.

Cite this